Small Cell Lung Cancer

New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.

New NCCN guidelines recommend lurbinectedin with atezolizumab as a first-line maintenance therapy for extensive-stage small cell lung cancer, enhancing treatment options.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic strategies for this aggressive disease.

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

FDA designates ifinatamab deruxtecan as a breakthrough therapy for extensive-stage small cell lung cancer, promising improved treatment options for patients.

Neoadjuvant immunotherapy combined with chemotherapy shows promising results in treating limited-stage small cell lung cancer, enhancing surgical outcomes and survival rates.

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with advanced solid tumors.

The NCCN added critical guidance on Lambert-Eaton myasthenic syndrome to its recommendation for the diagnosis and treatment of small cell lung cancer.

A multicenter study evaluating lurbinectedin in patients with extensive-stage small cell lung cancer who received second-line or later therapy demonstrated an objective response rate of 23.1% and a median overall survival of 5.4 months.

A recent trial reveals that targeted stereotactic radiation significantly reduces neurologic death rates in small cell lung cancer patients with brain metastases.

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with extensive-stage small cell lung cancer.

Explore the role of consolidative thoracic radiotherapy in enhancing survival for extensive-stage small cell lung cancer post-chemoimmunotherapy.

FDA prioritizes review of lurbinectedin and atezolizumab for first-line maintenance therapy in extensive-stage small cell lung cancer, promising improved survival rates.

LB2102 showed early antitumor activity and no DLTs in small cell lung cancer and large cell neuroendocrine carcinoma.

DeLLphi-304 trial results showed tarlatamab significantly improved PFS and OS over chemotherapy in second-line SCLC, establishing it as a new standard.

Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug conjugate for solid tumors.

Tarlatamab outperformed chemotherapy when used for the treatment of patients with small cell lung cancer in the phase 3 DeLLphi-304 trial.

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for extensive-stage small cell lung cancer.

Early trial results show combining the oncolytic virus olvi-vec with chemotherapy led to disease control and tolerable safety in extensive-stage small cell lung cancer.